Please login to the form below

Not currently logged in
Email:
Password:

Deal Watch table for April 2013

Table listing all the major pharma mergers, acquisitions and collaborations in the past month

This table lists all the major pharma collaborations, acquisitions and mergers during April 2013.

For an indepth analysis of these deals, read 'Pharma deals during April 2013'

Licensor acquired / licensee acquirer

Deal type

Product / technology

Headline ($m)

Conceptus/ Bayer

Acquisition

Birth control device

1,100

Actient Holdings/ Auxilium Pharmaceuticals

Acquisition

Urology specialty therapeutics company

585

Avalon/GSK

Funding

To fund up to 10 drug-discovery start-up companies over the next 3 years

495

Prolor Biotech/ Opkp Health

Acquisition

Longer-acting proprietary versions of approved therapeutic proteins

480

Isis Pharmaceuticals/ Roche

Collaboration

To develop treatments for Huntington's disease based on Isis' antisense oligonucleotide technology

392

Ambrx/ Astellas Pharma

Collaboration

Oncology discovery and development of novel antibody drug conjugates

300

Alchemia/ AstraZeneca

Collaboration

VAST discovery platform – multiple targets

240+

TaslyDiyi Pharma/ Tasly Pharmaceuticals

Acquisition

Maker of chemical drugs

240

Bavarian Nordic/ US Government

Award

Smallpox vaccine research

228

Bind Therapeutics/ Pfizer

Collaboration

Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins

210+

Ra Pharma/ Merck & Co

Collaboration

Extreme Diversity™ platform to develop Cyclomimetic candidates for protein targets in multiple therapeutic areas

200

Forma Therapeutics/ Celgene

Collaboration

Drug-discovery platform for compounds against protein homeostasis targets

200

Bind Therapeutics/ AstraZeneca

Collaboration

Employ the Medicinal Nanoengineering platform to develop and commercialise Accurins, based on an AZ kinase inhibitor

199

Velcera/ Perrigo Company

Acquisition

Pet health products

160

Santaris Pharma/ BMS

Collaboration

Discover and develop RNA-targeted therapies based on the LNA Drug platform

100

China Animal Health Care/ Elanco (Lilly)

Part acquisition

Manufacturing, sale and distribution of animal drugs in China 

100

Horizon Discovery/ AstraZeneca

Collaboration

Kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types

75

Achaogen/ Biomedical Advanced Research and Development Authority (BARDA)

Award

Phase 3 study - plazomicin to treat gram -ve bacterial infections due to Carbapenem-resistant Enterobacteriaceae

60

Pfizer/ Merck & Co*

Collaboration

Ertugliflozin as standalone and combination with Januvia and/or metformin for diabetes

60

Bracco Diagnostics/ Emergent BioSolutions

Asset purchase

Healthcare Protective Products Division

26

 

Unless noted all transactions are for global rights

*  Worldwide excluding Japan

The Deal Watch table is compiled my Medius Associates

8th May 2013

The Deal Watch table is compiled my Medius Associates

8th May 2013

From: Research, Sales

Share

Tags


Career advice

No results were found

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Infographics